Cognitive impairments associated with meningiomas and gliomas in adults: A systematic review.

NeuropsychologyJun 25, 2026 (epub)
Clinical ResearchNeurologyOncology (Medical)

Sara Goffinet, Xavier De Tiège, Florence Lefranc et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined cognitive impairments in adults with untreated meningiomas and gliomas, analyzing 70 studies involving 4,277 patients. The review found significant cognitive impairments across various domains, with memory and executive function deficits more common in gliomas, while meningiomas showed more executive and attentional impairments. The findings underscore the prevalence of cognitive issues in these patients.

Key findings

  • Cognitive impairments were prevalent across multiple domains in patients with meningiomas and gliomas.
  • Memory and executive impairments were more common in glioma patients.
  • Executive and attentional impairments predominated in meningioma patients.
  • The review included 70 studies with a total of 4,277 patients.

Why it matters

Understanding the cognitive impairments associated with meningiomas and gliomas is crucial for clinicians, as it can inform patient management and support strategies. Recognizing these impairments can lead to better care and improved quality of life for affected individuals.

Source

PubMed · PMID 42347767

Published in Neuropsychology. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.